linjc16/ctgov huggingface dataset:
Gene Expression in Predicting Outcome in Samples From Patients With High-Risk Neuroblastoma

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in RNA and predict how patients will respond to treatment. It may also help doctors find better ways to treat cancer. PURPOSE: This research trial studies gene expression in predicting outcomes in samples from patients with high-risk neuroblastoma.

Detailed Description
-----------------
OBJECTIVES: To test the correlation of a previously published microarray gene expression signature with the gene expression obtained with the nCounter™ Analysis System using RNA isolated from formalin-fixed, paraffin-embedded (FFPE), high-risk neuroblastoma samples. To construct, test, and validate a novel robust classifier that can be readily integrated into the clinic. OUTLINE: This is a multicenter study. RNA samples extracted from paraffin-embedded tissue are analyzed for gene signature expression levels by nCounter™ Analysis System and correlated with published microarray expression data. Results are then used to develop a refined gene-expression-profile classifier of ultra high-risk neuroblastoma.

Official Title
-----------------
Genome Based Outcome Prediction in High Risk Neuroblastoma

Conditions
-----------------
Neuroblastoma

Intervention / Treatment
-----------------
* Genetic: RNA analysis
* Genetic: gene expression analysis
* Other: laboratory biomarker analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Formalin-fixed paraffin-embedded tumor sections linked to clinical and outcome data collected from high-risk neuroblastoma patients (n=100) treated at the University of Chicago, St. Jude Children's Research Hospital, Children's Memorial Hospital, or Texas Children's Hospital PATIENT CHARACTERISTICS: Not specified PRIOR CONCURRENT THERAPY: Not specified
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Genetic: RNA analysis|nan|
|Genetic: gene expression analysis|nan|
|Other: laboratory biomarker analysis|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Linear correlation between the nCounter™ Analysis System and the expression data obtained in microarray platforms |  |  | 
| nCounter™ Analysis System and microarray platforms equally predictive of outcome in the high-risk group of neuroblastoma patients |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
disseminated neuroblastoma, localized unresectable neuroblastoma, recurrent neuroblastoma, regional neuroblastoma, stage 4S neuroblastoma
CapFlex-PIP© Motion

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to describe and to compare the motion analysis parameters, i.e. motion and stability of proximal interphalangeal joints, which were treated with a CapFlex-PIP© implant or silicone implant and to generate basic knowledge about motion analysis of untreated healthy hands.

Official Title
-----------------
Motion Analysis of the Proximal Interphalangeal Joint in Healthy Hands, as Well as in Osteoarthritis Hands Following Implantation With the New CapFlex-PIP© Implant Compared With Silicone Implants

Conditions
-----------------
Finger Joint, Arthroplasty, Replacement, Motion

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with proximal interphalangeal joint osteoarthritis in the index or middle finger, treated with a CapFlex-PIP© implant or with a silicone implant and with a follow-up time between 12 and 60 months after primary implantation or Patient with one untreated healthy hand without joint osteoarthritis Patient aged 50 years and over Patient willing and able to give written informed consent to participate in the study Exclusion Criteria: Inflammatory disease (e.g. rheumatoid arthritis) Pregnant women German language barrier to complete the questionnaires Any disease process that would preclude accurate evaluation (e.g. neuromuscular, psychiatric or metabolic disorder) Legal incompetence Participation in any other medical device or medicinal product study within the previous months that could influence the results of the present study

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients with CapFlex-PIP© implant<br> | |
| patients with silicone implant<br> | |
| patients with healthy PIP joints<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Active PIP joint range of motion (flexion and extension lag) during motion analysis |  | 1-5 years postoperative | 
| Lateral stability in coronal plane (to ulnar and radial side) during motion analysis |  | 1-5 years postoperative |
Study of the Effect of Lactisole on the Intestinal Glucose Uptake

Study Overview
=================
Brief Summary
-----------------
Study of the effect of lactisole on glucose uptake

Official Title
-----------------
Study on the Effect of Lactisole on the Intestinal Glucose Uptake

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Dietary Supplement: lactisole
* Other: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male subject, between 18 and 50 years General good health condition Exclusion Criteria: Overweight (Body Mass Index ≥30) Metabolic disorders History of gastrointestinal disorders Regular (daily) intake of medication Smoking more than 10 cigarettes/day History of drug abuse Exhaustive (> 3 units/day) alcohol consumption Exhaustive (> 5 units/day) caffeine consumption (coffee, tea, cola, or other caffeine based drinks) Recent (in the last 14 days) donation of blood Recent (in the last 2 days) donation of blood plasma Participation in another trial within 4 weeks before the start of the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>administration of lactisole | Dietary Supplement: lactisole<br>* administration of lactisole followed by placebo<br>|
| Placebo Comparator: 2<br>administration of placebo | Other: placebo<br>* administration of placebo followed by lactisole<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Differences in glucose uptake rate in lactisole treated subjects versus placebo treated subjects during oral glucose tolerance test |  | 5 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Differences in blood insulin, glucagon, triglycerides, GIP and GLP-1 in lactisole treated subjects versus placebo treated subjects during oral glucose tolerance test, ECG |  | 5 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Healthy volunteers
Multiregional rtfMRI Neurofeedback for the Prevention of Alzheimer's Disease (NPAD)

Study Overview
=================
Brief Summary
-----------------
This study aims to predict cognitive decline using a performance endophenotype of neuro-feedback based on functional magnetic resonance imaging in real time in a population at risk for Alzheimer's disease (AD).

Detailed Description
-----------------
In this research project, a longitudinal study in a healthy population that is under increased risk of developing AD will be performed. It is anticipated that some of the participating subjects will develop episodic memory decline within this longitudinal follow-up. The memory binding Test (MBT) and/or the Free and Cued Selective Reminding Test (FCSRT), the most accurate and reliable available episodic memory tests, are going to be performed by the subjects at multiple longitudinal data collection points. The project proposes to develop a real-time functional magnetic resonance imaging (rtfMRI) task, and to test whether the subjects' performance on the task can predict the apparition of cognitive decline. The impact of other relevant biomarkers by adding them to the model: age, gender, number of APOE-e4 alleles, cognitive scores, cerebrospinal fluid (CSF) biomarkers, amyloid Positron Emission Tomography (PET), lifestyle habits and clinical background will be studied.

Official Title
-----------------
Multiregional rtfMRI Neurofeedback for the Prevention of Alzheimer's Disease

Conditions
-----------------
Alzheimer Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult men and women (aged 45-75) that have participated in the study 45-65/FPM2012. Persons that accept the study's test and procedures that are as follows: magnetic resonance imaging and neuropsychological tests. Signature of the study's informed consent form, accepting to not receive information with regards to any research results that are not clinically relevant. Exclusion Criteria: Any contraindication to MRI (e.g. pacemaker, claustrophobia, etc.) Any condition that according to the investigator's judgement could interfere with the proper execution of the study's procedures and/or its follow-up.

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 79 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Adult children of AD patients<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in cognition | Predictive value of neurofeedback performance | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
neurofeedback, episodic memory, real-time functional MRI
Low Back Pain and Antibiotic Treatment

Study Overview
=================
Brief Summary
-----------------
Clinical trial using antibiotic treatment, namely Rulid, after onset of low back pain.

Detailed Description
-----------------
Clinical trial using antibiotic treatment, namely Rulid, after onset of low back pain.

Official Title
-----------------
Phase 1 Study of Antibiotic Treatment for Low Back Pain

Conditions
-----------------
Low Back Pain

Intervention / Treatment
-----------------
* Drug: Antibiotics


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Must be able to swallow tablets Exclusion Criteria: - Allergy to antibiotics

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Antibiotics|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| protocol designed to assess or examine persons or groups in a systematic way to identify specific markers for eligibility for further evaluation |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
low back pain
Study of Gonadotropin-Releasing Hormone Pulse Frequency in Sexual Maturation and in the Menstrual Cycle

Study Overview
=================
Brief Summary
-----------------
OBJECTIVES: I. Evaluate the sleep-entrained patterns of gonadotropin-releasing hormone (GnRH) and sex steroid secretion in normal and hypogonadal children. II. Examine the acute effects of sex steroids on the sleep-entrained patterns of GnRH secretion in pubertal children and normal adults, either by stimulation of endogenous production with pulsatile injection or by intravenous infusion of GnRH. III. Examine the role of endogenous opioids by means of opioid receptor blockade in the sex steroid regulation of GnRH secretion in pubertal children and normal adults.

Detailed Description
-----------------
PROTOCOL OUTLINE: This project involves several clinical protocols that study the regulation and role of pulsatile gonadotropin-releasing hormone (GnRH) secretion. Studies include dynamic and repeated stimulation tests of pulsatile GnRH; plasma luteinizing hormone, follicular-stimulating hormone, testosterone (T), estradiol (E2), and GnRH measurements at cyclic and episodic intervals; and evaluation of adrenal androgen patterns. Circadian rhythms of GnRH secretion are monitored during sleep and awake hours. Growth hormone secretory patterns and responses to provocative stimuli are studied as clinically indicated. Selected participants undergo an assessment of pituitary responsiveness following T, E2, and/or naloxone infusions. The suppressive effects of E2 are also studied during the early follicular phase of the menstrual cycle. Endocrinologically normal children and normal adult men and women are also studied.

Conditions
-----------------
Hypogonadism, Precocious Puberty

Participation Criteria
=================
Eligibility Criteria
-----------------
PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Suspected or proven hypothalamic-pituitary-gonadal dysfunction, i.e.: Significant short stature and possible hypopituitarism Delayed adolescence Precocious puberty Isolated growth hormone deficiency (IGHD)Primary hypogonadism Women are also studied, including those with the following disorders: Infertility Oligo- or amenorrhea Hirsutism --Patient Characteristics-- Age: 7 to 16 (18 to 35 for women and volunteers) Other: No pregnant or nursing women No prisoners Not in neuropsychiatric institute or other facility for mental illness

Ages Eligible for Study
-----------------
Minimum Age: 7 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
endocrine disorders, growth hormone deficiency, hypogonadism, precocious puberty, rare disease
Association Between Fear of Falling and Spinal Stiffness.

Study Overview
=================
Brief Summary
-----------------
/ evaluation of the fear of falling using an FES-I questionnaire, distribution of subjects according to the score into 3 groups (16-19: little concerned by the fear of falling, 20-27 moderately concerned, 28-64 very concerned by fear of falling) / evaluation of lumbar articular mobility by the schober index, coxofemoral by hip goniometry in flexion and extension (no evaluation of other amplitudes because lack of abduction / abduction / external and internal rotation of the hip remain functional in walking and the balance)

Detailed Description
-----------------
/ evaluation of the fear of falling using an FES-I questionnaire, distribution of subjects according to the score into 3 groups (16-19: little concerned by the fear of falling, 20-27 moderately concerned, 28-64 very concerned by fear of falling) / evaluation of lumbar articular mobility by the schober index, coxofemoral by hip goniometry in flexion and extension (no evaluation of other amplitudes because lack of abduction / abduction / external and internal rotation of the hip remain functional in walking and the balance)

Official Title
-----------------
L'Impact de la Raideur Articulaire Pelvienne Sur la Peur de Chuter du Sujet âgé hospitalisé ou en Institution.

Conditions
-----------------
Joint(S) Degeneration, Old Age; Atrophy, Fear of Injury

Intervention / Treatment
-----------------
* Diagnostic Test: anthropomorphic measurements


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: over 75 years old, Ability to understand and answer a questionnaire in French Ability to stand up Patient from the Melun hospital (santé pole center + nursing home of the GHSIF) Affiliated with a social security scheme Exclusion Criteria: mental disorders, lumbar surgery

Ages Eligible for Study
-----------------
Minimum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: anthropomorphic measurements|anthropomorphic measurements + FES questionnaire + demographic data and medications|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Association FES and goniometry | Highlight a significant positive association between hips' goniometry (angle degree) and FES-I score (continuous scale without unit) | 15 minutes | 
| Association FES-I (continuous scale without unit) and Schober index (centimeter) | Highlight a significant positive association between Shober index and FES-I score | 15 minutes |
Volatile Organic Compounds in Cystic Fibrosis

Study Overview
=================
Brief Summary
-----------------
This experiment is designed to test the effectiveness of a new electronic nose device, which allows a non-invasive breath test for markers of lower respiratory tract infection, which may predict the probability of bacterial organisms in the lower respiratory tract. It consists of: A breath collection apparatus for collection of volatile organic compounds in breath onto a sorbent trap and Tedlar bag, as well as for the collection of a separate sample of room air. Analysis of the volatile organic compounds in breath and room air by short acoustic wave/gas chromatography. Interpretation of the volatile organic compounds with a proprietary algorithm in order to predict the probability of lower respiratory tract colonization and infection. This study will test the hypothesis that the investigators can identify the presence of Pseudomonas aeruginosa by sampling the head space above culture media of sputum provided by patients with cystic fibrosis. This study will test the additional hypothesis that the investigators can identify the presence of Pseudomonas aeruginosa by sampling exhaled breath from the patient providing the sputum.

Official Title
-----------------
Detection of Pulmonary Colonization in Cystic Fibrosis Patients

Conditions
-----------------
Cystic Fibrosis, Pseudomonas Aeruginosa

Intervention / Treatment
-----------------
* Other: Cystic Fibrosis patients


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of Cystic Fibrosis Must be able to give breath and sputum samples Exclusion Criteria: Heavy smoker Inability to regularly give breath and sputum samples History of additional pulmonary disease

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cystic Fibrosis Patients<br>Patients with Cystic Fibrosis, some having Pseudomonas aeruginosa, some not. | Other: Cystic Fibrosis patients<br> <br> |
| Control<br>Healthy volunteers | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bacterial Identification | Patient's provided breath samples and sputum for culture. Bacterial identification by indices was achieved | six months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cystic Fibrosis, Pseudomonas aeruginosa, Volatile Organic Compounds, Electronic nose, Gas Chromatography
Mindfulness-based Crisis Intervention for COVID-19 Frontline Healthcare Workers During COVID-19

Study Overview
=================
Brief Summary
-----------------
The COVID-19 outbreak is having an impact on the well-being of healthcare workers. Previous reports on pandemics show that such an impact may last beyond the time of the outbreak. Mindfulness-based interventions help healthcare professionals to reduce stress and may foster resilience and recovery, although they have never been tested in a context such as the current one. This single-arm trial explores the acceptability, safety and usefulness of an on-site, brief Mindfulness-based intervention to reduce stress for front line health workers during a crisis.

Official Title
-----------------
Implementation of a Mindfulness-based Crisis Intervention for Frontline Healthcare Workers During the COVID-19 Outbreak in a Public General Hospital in Madrid, Spain

Conditions
-----------------
Mindfulness, COVID-19, Healthcare Worker

Intervention / Treatment
-----------------
* Other: Mindfulness based intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All frontline healthcare workers present in the ward at the time of intervention Exclusion Criteria: Extreme adverse events
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Mindfulness based intervention<br>Mindfulness based intervention for frontline healthcare workers during COVID-19 outbreak | Other: Mindfulness based intervention<br>* Mindfulness based intervention for frontline healthcare workers during COVID-19 outbreak<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Perceived helpfulness to reduce current stress | The outcome was measured by a 10-point visual analogue scale developed for this study, where 0 was it did not help me at all and 10 was it helped me a lot. | through study completion, up to three days |